

# The value of a risk prediction tool (PERSARC) for effective treatment decisions of soft tissue sarcomas patients.

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Pending
<b>Health condition type</b>	-
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON24454

### Source

NTR

### Brief title

VALUE-PERSARC

### Health condition

grade 2-3 soft tissue extremity sarcoma

## Sponsors and support

**Primary sponsor:** KWF kankerbestrijding

**Source(s) of monetary or material Support:** KWF kankerbestrijding (#12642)

## Intervention

## Outcome measures

### Primary outcome

The co-primary outcomes are decisional conflict (Decisional Conflict Scale(DCS)) and

informed choice. Informed choice is a combined outcome incorporating knowledge, attitudes concerning trade-offs between quality and length of life (QQ\_Questionnaire), and treatment decision.

## Secondary outcome

Secondary outcomes, include regret (Decision\_Regret\_Scale) (T3, T4), worry (Cancer\_Worry\_scale) (T1, T2, T3, T4), involvement in decision-making according to patients (SDM-Q-9) (T1), patient reported outcome using the Patient Reported Outcome Measures (PROMIS Global health) (T1, 2, 3, 4), and (PROMIS physical function) (T1, 2, 3, 4), utilities for the cost-effectiveness analysis (EQ-5D-5L) (T1, T2, T3, T4), health care cost (iMCQ) (T2, T3, T4) and absenteeism/presenteeism from paid work (T2, T3, T4).

## Study description

### Background summary

Currently, there is no consensus about the optimal treatment for patients with high grade soft tissue sarcomas (STS) which are localized in the extremities. To ensure overall survival, there is a tendency to operate with wide resection margins, but this has a high impact on quality of life especially when limb function must be sacrificed. (Neo)adjuvant radiotherapy allows for narrower surgical margins but is associated with significant short -and long-term side-effects. As evidence on the best treatment is lacking, treatment choice for individual patients should be driven by their weighing of the benefits and harms of the treatment options in light of their personal situation.

However, current treatment decision-making in STS care is one-size fits all, and not informed by individualized risks of treatment options and patients' preferences. Consequently, there is no guarantee that patients with STS will receive treatment that is appropriate for their situation, and patients experience uncertainty about which treatment is best for their personal situation (decisional conflict).

From literature it is known that decision supporting interventions contribute to a better informed choice and less decisional conflict. Therefore, our research group developed a validated personalized risk assessment tool (Personalised Sarcoma Care: PERSARC) which provides patients and STS professionals insight into the personalized risks and benefits of each treatment option based on patient's age, tumor size, tumor depth and histology in their decision-making process.

It is hypothesized that use of PERSARC leads to significantly less decisional conflict in patients and more informed decisions compared to usual care (treatment decisions without use of PERSARC) by reducing the uncertainty regarding risks and benefits of treatment options in high-grade extremity STS patients.

### Study objective

It is hypothesized that use of PERSARC leads to significantly less decisional conflict in

patients and more informed decisions compared to usual care (treatment decisions without use of PERSARC) by reducing the uncertainty regarding risks and benefits of treatment options in high-grade extremity STS patients.

## **Study design**

T1 (one week) T2 (3months) T3 (6months) T4 (12months) after treatment decision

## **Intervention**

High-grade extremity STS patients will either receive standard care (control group) or care with the use of PERSARC; i.e. PERSARC will be used in multidisciplinary tumour boards to guide treatment advice and in consultation in which the oncological/orthopaedic surgeon informs the patient about his/her diagnoses and discusses the benefits and harms of all relevant treatment options (intervention group).

## **Contacts**

### **Public**

LUMC

Anouk Kruiswijk

0631974532

### **Scientific**

LUMC

Anouk Kruiswijk

0631974532

## **Eligibility criteria**

### **Inclusion criteria**

Patients ( $\geq 18$  years) with primarily diagnosed (histologically confirmed) grade 2-3 extremity STS, who do not have a treatment plan yet and will be treated with curative intent. Patients with sarcoma subtypes or treatment options other than those mentioned in the PERSARC app are unable to participate. Furthermore, patients need to be Dutch fluency and literacy and mentally competent.

## Exclusion criteria

- Patient that are treated without curative intent
- Patient that needs to be treated with chemotherapy or isolated limb perfusion
- Patients where surgery is not indicated
- Sarcoma subtypes not mentioned in the PERSARC app

## Study design

### Design

Study type:	Interventional
Intervention model:	Crossover
Allocation:	Randomized controlled trial
Masking:	Single blinded (masking used)
Control:	Active

### Recruitment

NL	
Recruitment status:	Pending
Start date (anticipated):	01-08-2021
Enrollment:	231
Type:	Anticipated

### IPD sharing statement

**Plan to share IPD:** Undecided

## Ethics review

Positive opinion	
Date:	08-01-2021
Application type:	First submission

## Study registrations

### Followed up by the following (possibly more current) registration

ID: 51872

Bron: ToetsingOnline

Titel:

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
NTR-new	NL9160
CCMO	NL76563.058.21
OMON	NL-OMON51872

## Study results